Signant’s RTSM Manages Clinical IP Dispensation in Schizophrenia Study Date Published: Oct 24, 2022 Case Study A pharmaceutical company needed to ensure proper dispensation of their investigational product (IP) around variable visit schedules across multiple patient subgroups, as well as ensure each patient had sufficient doses to last until their next visit without incurring waste. The company selected our Signant SmartSignals RTSM solution to help: Maintain study balance across multiple strata and subgroupsPrevent IP allocation to duplicate subjectsManage the return and destruction of supplies in all cases as needed, including early patient termination Download the case study below and visit our RTSM page to learn more. Learn More Share: LinkedInTweet Recommended Resources RTSM: The Present and Future of Study Supply Management Watch Now Webinar Direct-to-Patient RTSM Download Now Brochure Lessons in Direct-To-Patient RTSM Models Download Now Whitepaper